<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39204409</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1999-4923</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>13</Day></PubDate></JournalIssue><Title>Pharmaceutics</Title><ISOAbbreviation>Pharmaceutics</ISOAbbreviation></Journal><ArticleTitle>Immunomodulatory R848-Loaded Anti-PD-L1-Conjugated Reduced Graphene Oxide Quantum Dots for Photothermal Immunotherapy of Glioblastoma.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1064</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmaceutics16081064</ELocationID><Abstract><AbstractText>Glioblastoma multiforme (GBM) is the most severe form of brain cancer and presents unique challenges to developing novel treatments due to its immunosuppressive milieu where receptors like programmed death ligand 1 (PD-L1) are frequently elevated to prevent an effective anti-tumor immune response. To potentially shift the GBM environment from being immunosuppressive to immune-enhancing, we engineered a novel nanovehicle from reduced graphene oxide quantum dot (rGOQD), which are loaded with the immunomodulatory drug resiquimod (R848) and conjugated with an anti-PD-L1 antibody (aPD-L1). The immunomodulatory rGOQD/R8/aPDL1 nanoparticles can actively target the PD-L1 on the surface of ALTS1C1 murine glioblastoma cells and release R848 to enhance the T-cell-driven anti-tumor response. From in vitro experiments, the PD-L1-mediated intracellular uptake and the rGOQD-induced photothermal response after irradiation with near-infrared laser light led to the death of cancer cells and the release of damage-associated molecular patterns (DAMPs). The combinational effect of R848 and released DAMPs synergistically produces antigens to activate dendritic cells, which can prime T lymphocytes to infiltrate the tumor in vivo. As a result, T cells effectively target and attack the PD-L1-suppressed glioma cells and foster a robust photothermal therapy elicited anti-tumor immune response from a syngeneic mouse model of GBM with subcutaneously implanted ALTS1C1 cells.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yu-Jen</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Chang Gung Memorial Hospital at Linkou, Kwei-San, Taoyuan 33305, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine, Chang Gung University, Kwei-San, Taoyuan 33302, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vayalakkara</LastName><ForeName>Reesha Kakkadavath</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Chang Gung Memorial Hospital at Linkou, Kwei-San, Taoyuan 33305, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dash</LastName><ForeName>Banendu Sunder</ForeName><Initials>BS</Initials><Identifier Source="ORCID">0000-0002-7546-3902</Identifier><AffiliationInfo><Affiliation>Department of Chemical and Materials and Materials Engineering, Chang Gung University, Kwei-San, Taoyuan 33302, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Shang-Hsiu</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0002-8965-3918</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 300044, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Premji</LastName><ForeName>Thejas Pandaraparambil</ForeName><Initials>TP</Initials><AffiliationInfo><Affiliation>Department of Chemical and Materials and Materials Engineering, Chang Gung University, Kwei-San, Taoyuan 33302, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chun-Yuan</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Chang Gung Memorial Hospital at Linkou, Kwei-San, Taoyuan 33305, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Yang-Jin</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Chang Gung Memorial Hospital at Linkou, Kwei-San, Taoyuan 33305, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jyh-Ping</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0001-6527-4801</Identifier><AffiliationInfo><Affiliation>Department of Neurosurgery, Chang Gung Memorial Hospital at Linkou, Kwei-San, Taoyuan 33305, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemical and Materials and Materials Engineering, Chang Gung University, Kwei-San, Taoyuan 33302, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Center for Food and Cosmetic Safety, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan 33302, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Materials Engineering, Ming Chi University of Technology, Tai-Shan, New Taipei City 24301, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CMRPG3M1362, CORPG3L0061 and CMRPD2N0091</GrantID><Agency>Linkou Chang Gung Memorial Hospital</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceutics</MedlineTA><NlmUniqueID>101534003</NlmUniqueID><ISSNLinking>1999-4923</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">R848</Keyword><Keyword MajorTopicYN="N">anti-PD-L1</Keyword><Keyword MajorTopicYN="N">glioblastoma</Keyword><Keyword MajorTopicYN="N">graphene oxide quantum dot</Keyword><Keyword MajorTopicYN="N">immunotherapy</Keyword><Keyword MajorTopicYN="N">photothermal therapy</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>29</Day><Hour>1</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39204409</ArticleId><ArticleId IdType="pmc">PMC11358977</ArticleId><ArticleId IdType="doi">10.3390/pharmaceutics16081064</ArticleId><ArticleId IdType="pii">pharmaceutics16081064</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rocha Pinheiro S.L., Lemos F.F.B., Marques H.S., Silva Luz M., de Oliveira Silva L.G., Dos Santos C.F.S.M., da Costa Evangelista K., Calmon M.S., Sande Loureiro M., de Melo F.F. Immunotherapy in glioblastoma treatment: Current state and future prospects. World J. Clin. Oncol. 2023;14:138–159. doi: 10.5306/wjco.v14.i4.138.</Citation><ArticleIdList><ArticleId IdType="doi">10.5306/wjco.v14.i4.138</ArticleId><ArticleId IdType="pmc">PMC10134201</ArticleId><ArticleId IdType="pubmed">37124134</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller M., van den Bent M., Preusser M., Le Rhun E., Tonn J.C., Minniti G., Bendszus M., Balana C., Chinot O., Dirven L., et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat. Rev. Clin. Oncol. 2021;18:170–186. doi: 10.1038/s41571-020-00447-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-020-00447-z</ArticleId><ArticleId IdType="pmc">PMC7904519</ArticleId><ArticleId IdType="pubmed">33293629</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Zhao L., Zhang H., Zhang Y., Ju H., Wang X., Ren H., Zhu X., Dong Y. The immunosuppressive microenvironment and immunotherapy in human glioblastoma. Front. Immunol. 2022;13:1003651. doi: 10.3389/fimmu.2022.1003651.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1003651</ArticleId><ArticleId IdType="pmc">PMC9712217</ArticleId><ArticleId IdType="pubmed">36466873</ArticleId></ArticleIdList></Reference><Reference><Citation>Pombo Antunes A.R., Scheyltjens I., Duerinck J., Neyns B., Movahedi K., Van Ginderachter J.A. Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies. eLife. 2020;9:e52176. doi: 10.7554/eLife.52176.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.52176</ArticleId><ArticleId IdType="pmc">PMC7000215</ArticleId><ArticleId IdType="pubmed">32014107</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanelli G.N., Grassini D., Ortenzi V., Pasqualetti F., Montemurro N., Perrini P., Naccarato A.G., Scatena C. Decipher the Glioblastoma Microenvironment: The First Milestone for New Groundbreaking Therapeutic Strategies. Genes. 2021;12:445. doi: 10.3390/genes12030445.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes12030445</ArticleId><ArticleId IdType="pmc">PMC8003887</ArticleId><ArticleId IdType="pubmed">33804731</ArticleId></ArticleIdList></Reference><Reference><Citation>Turco V., Pfleiderer K., Hunger J., Horvat N.K., Karimian-Jazi K., Schregel K., Fischer M., Brugnara G., Jähne K., Sturm V., et al. T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles. Nat. Commun. 2023;14:771. doi: 10.1038/s41467-023-36321-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-36321-6</ArticleId><ArticleId IdType="pmc">PMC9922247</ArticleId><ArticleId IdType="pubmed">36774352</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H.T., Huang H.C., Chung C.W., Chiang C.C., Hsia T., Wu H.F., Huang R.L., Chiang C.S., Wang J., Lu T.T., et al. CXCR4-targeted nitric oxide nanoparticles deliver PD-L1 siRNA for immunotherapy against glioblastoma. J. Control. Release. 2022;352:920–930. doi: 10.1016/j.jconrel.2022.10.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2022.10.047</ArticleId><ArticleId IdType="pubmed">36334859</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P., Miska J., Lee-Chang C., Rashidi A., Panek W.K., An S., Zannikou M., Lopez-Rosas A., Han Y., Xiao T., et al. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma. Proc. Natl. Acad. Sci. USA. 2019;116:23714–23723. doi: 10.1073/pnas.1906346116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1906346116</ArticleId><ArticleId IdType="pmc">PMC6876152</ArticleId><ArticleId IdType="pubmed">31712430</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghouzlani A., Kandoussi S., Tall M., Reddy K.P., Rafii S., Badou A. Immune Checkpoint Inhibitors in Human Glioma Microenvironment. Front. Immunol. 2021;12:679425. doi: 10.3389/fimmu.2021.679425.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.679425</ArticleId><ArticleId IdType="pmc">PMC8301219</ArticleId><ArticleId IdType="pubmed">34305910</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T., Kong Z., Ma W. PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: Clinical studies, challenges and potential. Hum. Vaccin. Immunother. 2021;17:546–553. doi: 10.1080/21645515.2020.1782692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1782692</ArticleId><ArticleId IdType="pmc">PMC7899692</ArticleId><ArticleId IdType="pubmed">32643507</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert C., Schachter J., Long G.V., Arance A., Grob J.J., Mortier L., Daud A., Carlino M.S., McNeil C., Lotem M., et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 2015;372:2521–2532. doi: 10.1056/NEJMoa1503093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1503093</ArticleId><ArticleId IdType="pubmed">25891173</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbst R.S., Baas P., Kim D.W., Felip E., Pérez-Gracia J.L., Han J.Y., Molina J., Kim J.H., Arvis C.D., Ahn M.J., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet. 2016;387:1540–1550. doi: 10.1016/S0140-6736(15)01281-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)01281-7</ArticleId><ArticleId IdType="pubmed">26712084</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S., Dash B.S., Premji T.P., Chen J.P. Immunotherapeutic Approaches for the Treatment of Glioblastoma Multiforme: Mechanism and Clinical Applications. Int. J. Mol. Sci. 2023;24:546. doi: 10.3390/ijms241310546.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241310546</ArticleId><ArticleId IdType="pmc">PMC10341481</ArticleId><ArticleId IdType="pubmed">37445721</ArticleId></ArticleIdList></Reference><Reference><Citation>Lathia J.D., Mack S.C., Mulkearns-Hubert E.E., Valentim C.L., Rich J.N. Cancer stem cells in glioblastoma. Genes Dev. 2015;29:1203–1217. doi: 10.1101/gad.261982.115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.261982.115</ArticleId><ArticleId IdType="pmc">PMC4495393</ArticleId><ArticleId IdType="pubmed">26109046</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan M., Liu Y., Zhu X., Wang X., Liu L., Sun H., Wang C., Kong D., Ma G. Nanoscale Reduced Graphene Oxide-Mediated Photothermal Therapy Together with IDO Inhibition and PD-L1 Blockade Synergistically Promote Antitumor Immunity. ACS Appl. Mater. Interfaces. 2019;11:1876–1885. doi: 10.1021/acsami.8b18751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.8b18751</ArticleId><ArticleId IdType="pubmed">30582788</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie N., Shen G., Gao W., Huang Z., Huang C., Fu L. Neoantigens: Promising targets for cancer therapy. Signal Transduct. Target. Ther. 2023;8:9. doi: 10.1038/s41392-022-01270-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01270-x</ArticleId><ArticleId IdType="pmc">PMC9816309</ArticleId><ArticleId IdType="pubmed">36604431</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubin M.M., Zhang X., Schuster H., Caron E., Ward J.P., Noguchi T., Ivanova Y., Hundal J., Arthur C.D., Krebber W.-J., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515:577–581. doi: 10.1038/nature13988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13988</ArticleId><ArticleId IdType="pmc">PMC4279952</ArticleId><ArticleId IdType="pubmed">25428507</ArticleId></ArticleIdList></Reference><Reference><Citation>Fucikova J., Kepp O., Kasikova L., Petroni G., Yamazaki T., Liu P., Zhao L., Spisek R., Kroemer G., Galluzzi L. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 2020;11:1013. doi: 10.1038/s41419-020-03221-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-03221-2</ArticleId><ArticleId IdType="pmc">PMC7691519</ArticleId><ArticleId IdType="pubmed">33243969</ArticleId></ArticleIdList></Reference><Reference><Citation>Krysko D.V., Garg A.D., Kaczmarek A., Krysko O., Agostinis P., Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer. 2012;12:860–875. doi: 10.1038/nrc3380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc3380</ArticleId><ArticleId IdType="pubmed">23151605</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed A., Tait S.W.G. Targeting immunogenic cell death in cancer. Mol. Oncol. 2020;14:2994–3006. doi: 10.1002/1878-0261.12851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1878-0261.12851</ArticleId><ArticleId IdType="pmc">PMC7718954</ArticleId><ArticleId IdType="pubmed">33179413</ArticleId></ArticleIdList></Reference><Reference><Citation>Roh J.S., Sohn D.H. Damage-Associated Molecular Patterns in Inflammatory Diseases. Immune Netw. 2018;18:e27. doi: 10.4110/in.2018.18.e27.</Citation><ArticleIdList><ArticleId IdType="doi">10.4110/in.2018.18.e27</ArticleId><ArticleId IdType="pmc">PMC6117512</ArticleId><ArticleId IdType="pubmed">30181915</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X., Yang K., Zhao R., Ji T., Wang X., Yang X., Zhang Y., Cheng K., Liu S., Hao J., et al. Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. Biomaterials. 2016;102:187–197. doi: 10.1016/j.biomaterials.2016.06.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2016.06.032</ArticleId><ArticleId IdType="pubmed">27343466</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourgholi F., Hajivalili M., Farhad J.N., Kafil H.S., Yousefi M. Nanoparticles: Novel vehicles in treatment of Glioblastoma. Biomed. Pharmacother. 2016;77:98–107. doi: 10.1016/j.biopha.2015.12.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2015.12.014</ArticleId><ArticleId IdType="pubmed">26796272</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T.-I., Tsai Y.-C., Wang T.-M., Chang S.-H., Yang Y.-C., Chen H.-H., Chiu H.-C. Development of a nano-immunomodulator encapsulating R837 and caffeine for combined radio-/immunotherapy against orthotopic breast cancer. Prog. Nat. Sci. Mater. Int. 2020;30:697–706. doi: 10.1016/j.pnsc.2020.09.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnsc.2020.09.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M., Wang W., Mohammadniaei M., Zheng T., Zhang Q., Ashley J., Liu S., Sun Y., Tang B.Z. Upregulating Aggregation-Induced-Emission Nanoparticles with Blood–Tumor-Barrier Permeability for Precise Photothermal Eradication of Brain Tumors and Induction of Local Immune Responses. Adv. Mater. 2021;33:2008802. doi: 10.1002/adma.202008802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.202008802</ArticleId><ArticleId IdType="pubmed">33893670</ArticleId></ArticleIdList></Reference><Reference><Citation>Szopa W., Burley T.A., Kramer-Marek G., Kaspera W. Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives. Biomed Res. Int. 2017;2017:8013575. doi: 10.1155/2017/8013575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/8013575</ArticleId><ArticleId IdType="pmc">PMC5337853</ArticleId><ArticleId IdType="pubmed">28316990</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Wang M., Zhou B., Zhou F., Murray C., Towner R.A., Smith N., Saunders D., Xie G., Chen W.R. PEGylated reduced-graphene oxide hybridized with Fe3O4 nanoparticles for cancer photothermal-immunotherapy. J. Mater. Chem. B. 2019;7:7406–7414. doi: 10.1039/C9TB00630C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C9TB00630C</ArticleId><ArticleId IdType="pmc">PMC7003986</ArticleId><ArticleId IdType="pubmed">31710067</ArticleId></ArticleIdList></Reference><Reference><Citation>Galluzzi L., Buqué A., Kepp O., Zitvogel L., Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 2017;17:97–111. doi: 10.1038/nri.2016.107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.107</ArticleId><ArticleId IdType="pubmed">27748397</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney E.E., Cano-Mejia J., Fernandes R. Photothermal Therapy Generates a Thermal Window of Immunogenic Cell Death in Neuroblastoma. Small. 2018;14:e1800678. doi: 10.1002/smll.201800678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/smll.201800678</ArticleId><ArticleId IdType="pubmed">29665282</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P.M., Pan W.Y., Wu C.Y., Yeh C.Y., Korupalli C., Luo P.K., Chou C.J., Chia W.T., Sung H.W. Modulation of tumor microenvironment using a TLR-7/8 agonist-loaded nanoparticle system that exerts low-temperature hyperthermia and immunotherapy for in situ cancer vaccination. Biomaterials. 2020;230:119629. doi: 10.1016/j.biomaterials.2019.119629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2019.119629</ArticleId><ArticleId IdType="pubmed">31767446</ArticleId></ArticleIdList></Reference><Reference><Citation>Burley T.A., Mączyńska J., Shah A., Szopa W., Harrington K.J., Boult J.K.R., Mrozek-Wilczkiewicz A., Vinci M., Bamber J.C., Kaspera W., et al. Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment. Int. J. Cancer. 2018;142:2363–2374. doi: 10.1002/ijc.31246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.31246</ArticleId><ArticleId IdType="pmc">PMC6016485</ArticleId><ArticleId IdType="pubmed">29313975</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata S., Shinozaki N., Suganami A., Ikegami S., Kinoshita Y., Hasegawa R., Kentaro H., Okamoto Y., Aoki I., Tamura Y., et al. Photo-immune therapy with liposomally formulated phospholipid-conjugated indocyanine green induces specific antitumor responses with heat shock protein-70 expression in a glioblastoma model. Oncotarget. 2019;10:175–183. doi: 10.18632/oncotarget.26544.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.26544</ArticleId><ArticleId IdType="pmc">PMC6349435</ArticleId><ArticleId IdType="pubmed">30719212</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R., Groer C., Kleindl P.A., Moulder K.R., Huang A., Hunt J.R., Cai S., Aires D.J., Berkland C., Forrest M.L. Formulation and preclinical evaluation of a toll-like receptor 7/8 agonist as an anti-tumoral immunomodulator. J. Control. Release. 2019;306:165–176. doi: 10.1016/j.jconrel.2019.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2019.06.003</ArticleId><ArticleId IdType="pmc">PMC6679596</ArticleId><ArticleId IdType="pubmed">31173789</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodell C.B., Arlauckas S.P., Cuccarese M.F., Garris C.S., Li R., Ahmed M.S., Kohler R.H., Pittet M.J., Weissleder R. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat. Biomed. Eng. 2018;2:578–588. doi: 10.1038/s41551-018-0236-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41551-018-0236-8</ArticleId><ArticleId IdType="pmc">PMC6192054</ArticleId><ArticleId IdType="pubmed">31015631</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K., Qu S., Chen X., Wu Q., Shi M. Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways. Int. J. Mol. Sci. 2017;18:404. doi: 10.3390/ijms18020404.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18020404</ArticleId><ArticleId IdType="pmc">PMC5343938</ArticleId><ArticleId IdType="pubmed">28216575</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Q., Qi S., Li P., Yang L., Yang S., Wang Y., Cheng Y., Song Y., Wang S., Tan F., et al. Photothermally activatable PDA immune nanomedicine combined with PD-L1 checkpoint blockade for antimetastatic cancer photoimmunotherapy. J. Mater. Chem. B. 2019;7:2499–2511. doi: 10.1039/C9TB00089E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C9TB00089E</ArticleId><ArticleId IdType="pubmed">32255127</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C., Hong H., Lee Y., Park K.S., Sun M., Wang T., Aikins M.E., Xu Y., Moon J.J. Efficient Lymph Node-Targeted Delivery of Personalized Cancer Vaccines with Reactive Oxygen Species-Inducing Reduced Graphene Oxide Nanosheets. ACS Nano. 2020;14:13268–13278. doi: 10.1021/acsnano.0c05062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.0c05062</ArticleId><ArticleId IdType="pmc">PMC7606610</ArticleId><ArticleId IdType="pubmed">32902245</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor K., Tabish T.A., Narayan R.J. Drug Release Kinetics of DOX-Loaded Graphene-Based Nanocarriers for Ovarian and Breast Cancer Therapeutics. Appl. Sci. 2021;11:11151. doi: 10.3390/app112311151.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/app112311151</ArticleId></ArticleIdList></Reference><Reference><Citation>Dash B.S., Jose G., Lu Y.-J., Chen J.-P. Functionalized Reduced Graphene Oxide as a Versatile Tool for Cancer Therapy. Int. J. Mol. Sci. 2021;22:2989. doi: 10.3390/ijms22062989.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22062989</ArticleId><ArticleId IdType="pmc">PMC8000837</ArticleId><ArticleId IdType="pubmed">33804239</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao L., Song H., Zhan Z., Lv Y. Multifunctional Reduced Graphene Oxide-Based Nanoplatform for Synergistic Targeted Chemo-Photothermal Therapy. ACS Appl. Bio Mater. 2020;3:5213–5222. doi: 10.1021/acsabm.0c00614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsabm.0c00614</ArticleId><ArticleId IdType="pubmed">35021696</ArticleId></ArticleIdList></Reference><Reference><Citation>Dash B.S., Lu Y.-J., Pejrprim P., Lan Y.-H., Chen J.-P. Hyaluronic acid-modified, IR780-conjugated and doxorubicin-loaded reduced graphene oxide for targeted cancer chemo/photothermal/photodynamic therapy. Biomater. Adv. 2022;136:212764. doi: 10.1016/j.bioadv.2022.212764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioadv.2022.212764</ArticleId><ArticleId IdType="pubmed">35929292</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarepour A., Khosravi A., Yücel Ayten N., Çakır Hatır P., Iravani S., Zarrabi A. Innovative approaches for cancer treatment: Graphene quantum dots for photodynamic and photothermal therapies. J. Mater. Chem. B. 2024;12:4307–4334. doi: 10.1039/D4TB00255E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D4TB00255E</ArticleId><ArticleId IdType="pubmed">38595268</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H., Kuila T., Kim N.H., Ku B.-C., Lee J.H. In situ synthesis of the reduced graphene oxide–polyethyleneimine composite and its gas barrier properties. J. Mater. Chem. A. 2013;1:3739–3746. doi: 10.1039/c3ta01228j.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c3ta01228j</ArticleId></ArticleIdList></Reference><Reference><Citation>Dash B.S., Lu Y.-J., Chen J.-P. Enhancing Photothermal/Photodynamic Therapy for Glioblastoma by Tumor Hypoxia Alleviation and Heat Shock Protein Inhibition Using IR820-Conjugated Reduced Graphene Oxide Quantum Dots. ACS Appl. Mater. Interfaces. 2024;16:13543–13562. doi: 10.1021/acsami.3c19152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.3c19152</ArticleId><ArticleId IdType="pubmed">38452225</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins M., Turner B., Rivera K., Menegatti S., Daniele M. Quantum dot enabled lateral flow immunoassay for detection of cardiac biomarker NT-proBNP. Sens. Bio-Sens. Res. 2018;21:46–53. doi: 10.1016/j.sbsr.2018.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sbsr.2018.10.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Q., Lin Y., Kawabata Y., Jia Y., Zhang P., Akther N., Guan K., Yoshioka T., Shon H., Matsuyama H. Engineering Heterostructured Thin-Film Nanocomposite Membrane with Functionalized Graphene Oxide Quantum Dots (GOQD) for Highly Efficient Reverse Osmosis. ACS Appl. Mater. Interfaces. 2020;12:38662–38673. doi: 10.1021/acsami.0c10301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.0c10301</ArticleId><ArticleId IdType="pubmed">32693571</ArticleId></ArticleIdList></Reference><Reference><Citation>Dash B.S., Lu Y.J., Chen H.A., Chuang C.C., Chen J.P. Magnetic and GRPR-targeted reduced graphene oxide/doxorubicin nanocomposite for dual-targeted chemo-photothermal cancer therapy. Mater. Sci. Eng. C Mater. Biol. Appl. 2021;128:112311. doi: 10.1016/j.msec.2021.112311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msec.2021.112311</ArticleId><ArticleId IdType="pubmed">34474862</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashemi M., Omidi M., Muralidharan B., Smyth H., Mohagheghi M.A., Mohammadi J., Milner T.E. Evaluation of the Photothermal Properties of a Reduced Graphene Oxide/Arginine Nanostructure for Near-Infrared Absorption. ACS Appl. Mater. Interfaces. 2017;9:32607–32620. doi: 10.1021/acsami.7b11291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.7b11291</ArticleId><ArticleId IdType="pubmed">28841283</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghi M.S., Sangrizeh F.H., Jahani N., Abedin M.S., Chaleshgari S., Ardakan A.K., Baeelashaki R., Ranjbarpazuki G., Rahmanian P., Zandieh M.A., et al. Graphene oxide nanoarchitectures in cancer therapy: Drug and gene delivery, phototherapy, immunotherapy, and vaccine development. Environ. Res. 2023;237:117027. doi: 10.1016/j.envres.2023.117027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envres.2023.117027</ArticleId><ArticleId IdType="pubmed">37659647</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D., Kim H. Optimization of Photothermal Therapy Treatment Effect under Various Laser Irradiation Conditions. Int. J. Mol. Sci. 2022;23:5928. doi: 10.3390/ijms23115928.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23115928</ArticleId><ArticleId IdType="pmc">PMC9180462</ArticleId><ArticleId IdType="pubmed">35682607</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C., Song X., Liu Y., Fu Y., Ye L., Wang N., Wang F., Li L., Mohammadniaei M., Zhang M., et al. Synthesis of graphene quantum dots and their applications in drug delivery. J. Nanobiotechnol. 2020;18:142. doi: 10.1186/s12951-020-00698-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12951-020-00698-z</ArticleId><ArticleId IdType="pmc">PMC7532648</ArticleId><ArticleId IdType="pubmed">33008457</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin S., Chen Z., Chen D., Yan D. Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy. Theranostics. 2023;13:1520–1544. doi: 10.7150/thno.80091.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.80091</ArticleId><ArticleId IdType="pmc">PMC10086210</ArticleId><ArticleId IdType="pubmed">37056572</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Zhang H., Cui L., Wang X., Wang D., Liu Z., Zhang X., Tang Z. An MMAE-loaded PDL1 active targeting nanomedicine for the precision treatment of colon cancer. Biomater. Sci. 2023;11:5195–5204. doi: 10.1039/D3BM00664F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D3BM00664F</ArticleId><ArticleId IdType="pubmed">37337707</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez C., Huebener P., Schwabe R.F. Damage-associated molecular patterns in cancer: A double-edged sword. Oncogene. 2016;35:5931–5941. doi: 10.1038/onc.2016.104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2016.104</ArticleId><ArticleId IdType="pmc">PMC5119456</ArticleId><ArticleId IdType="pubmed">27086930</ArticleId></ArticleIdList></Reference><Reference><Citation>Obeid M., Panaretakis T., Joza N., Tufi R., Tesniere A., van Endert P., Zitvogel L., Kroemer G. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ. 2007;14:1848–1850. doi: 10.1038/sj.cdd.4402201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cdd.4402201</ArticleId><ArticleId IdType="pubmed">17657249</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerner E.C., Edwards R.M., Wilkinson D.S., Fecci P.E. Laser ablation: Heating up the anti-tumor response in the intracranial compartment. Adv. Drug Deliv. Rev. 2022;185:114311. doi: 10.1016/j.addr.2022.114311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2022.114311</ArticleId><ArticleId IdType="pmc">PMC10589123</ArticleId><ArticleId IdType="pubmed">35489652</ArticleId></ArticleIdList></Reference><Reference><Citation>Attia M.F., Anton N., Wallyn J., Omran Z., Vandamme T.F. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J. Pharm. Pharmacol. 2019;71:1185–1198. doi: 10.1111/jphp.13098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jphp.13098</ArticleId><ArticleId IdType="pubmed">31049986</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekhri P., Ledezma D.K., Shukla A., Sweeney E.E., Fernandes R. The Thermal Dose of Photothermal Therapy Generates Differential Immunogenicity in Human Neuroblastoma Cells. Cancers. 2022;14:1447. doi: 10.3390/cancers14061447.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14061447</ArticleId><ArticleId IdType="pmc">PMC8945975</ArticleId><ArticleId IdType="pubmed">35326601</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammer G.E., Ma A. Molecular control of steady-state dendritic cell maturation and immune homeostasis. Annu. Rev. Immunol. 2013;31:743–791. doi: 10.1146/annurev-immunol-020711-074929.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-020711-074929</ArticleId><ArticleId IdType="pmc">PMC4091962</ArticleId><ArticleId IdType="pubmed">23330953</ArticleId></ArticleIdList></Reference><Reference><Citation>Marciscano A.E., Anandasabapathy N. The role of dendritic cells in cancer and anti-tumor immunity. Semin. Immunol. 2021;52:101481. doi: 10.1016/j.smim.2021.101481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2021.101481</ArticleId><ArticleId IdType="pmc">PMC8545750</ArticleId><ArticleId IdType="pubmed">34023170</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M.K., Kim J. Properties of immature and mature dendritic cells: Phenotype, morphology, phagocytosis, and migration. RSC Adv. 2019;9:11230–11238. doi: 10.1039/C9RA00818G.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C9RA00818G</ArticleId><ArticleId IdType="pmc">PMC9063012</ArticleId><ArticleId IdType="pubmed">35520256</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudek A.M., Martin S., Garg A.D., Agostinis P. Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity. Front. Immunol. 2013;4:438. doi: 10.3389/fimmu.2013.00438.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2013.00438</ArticleId><ArticleId IdType="pmc">PMC3858649</ArticleId><ArticleId IdType="pubmed">24376443</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong S., Jang N., Kim M., Choi I.K. CD4+ cytotoxic T cells: An emerging effector arm of anti-tumor immunity. BMB Rep. 2023;56:140–144. doi: 10.5483/BMBRep.2023-0014.</Citation><ArticleIdList><ArticleId IdType="doi">10.5483/BMBRep.2023-0014</ArticleId><ArticleId IdType="pmc">PMC10068340</ArticleId><ArticleId IdType="pubmed">36863358</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng W., Li Z., Chen H., Zeng X., Mei L. An optimal portfolio of photothermal combined immunotherapy. Cell Rep. Phys. Sci. 2022;3:100898. doi: 10.1016/j.xcrp.2022.100898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrp.2022.100898</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>